UniSa - IRIS Institutional Research Information System

PEPE, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.231
EU - Europa 2.667
AS - Asia 2.204
SA - Sud America 252
Continente sconosciuto - Info sul continente non disponibili 31
AF - Africa 19
OC - Oceania 5
Totale 15.409
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.210
CN - Cina 836
UA - Ucraina 759
SG - Singapore 649
IT - Italia 557
DE - Germania 349
RU - Federazione Russa 325
VN - Vietnam 291
IE - Irlanda 265
BR - Brasile 233
FI - Finlandia 205
KR - Corea 161
TR - Turchia 149
SE - Svezia 84
IN - India 40
EU - Europa 30
AT - Austria 28
GB - Regno Unito 25
HK - Hong Kong 22
CZ - Repubblica Ceca 20
FR - Francia 18
CA - Canada 13
JO - Giordania 10
NL - Olanda 9
IQ - Iraq 8
JP - Giappone 7
AR - Argentina 6
IL - Israele 6
PL - Polonia 6
MA - Marocco 5
PK - Pakistan 5
DZ - Algeria 4
EC - Ecuador 4
AL - Albania 3
BG - Bulgaria 3
CO - Colombia 3
CR - Costa Rica 3
ID - Indonesia 3
KG - Kirghizistan 3
NP - Nepal 3
NZ - Nuova Zelanda 3
UZ - Uzbekistan 3
AU - Australia 2
CL - Cile 2
EG - Egitto 2
GR - Grecia 2
IR - Iran 2
LT - Lituania 2
MX - Messico 2
NO - Norvegia 2
RO - Romania 2
TN - Tunisia 2
VE - Venezuela 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BD - Bangladesh 1
BH - Bahrain 1
BY - Bielorussia 1
ES - Italia 1
GT - Guatemala 1
JM - Giamaica 1
KE - Kenya 1
LB - Libano 1
MK - Macedonia 1
MM - Myanmar 1
MU - Mauritius 1
NG - Nigeria 1
PA - Panama 1
PE - Perù 1
SN - Senegal 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 15.409
Salva come PNG Salva come JPEG
Città #
Ann Arbor 2.852
Woodbridge 1.235
Wilmington 1.081
Jacksonville 921
Houston 904
Chandler 793
Princeton 663
Beijing 292
Dong Ket 290
Dublin 262
Ashburn 237
Singapore 202
Andover 172
Nanjing 150
Izmir 144
Pellezzano 125
Boardman 124
Mestre 107
Munich 105
Moscow 87
Düsseldorf 67
Fairfield 55
Nanchang 50
Naples 50
Shenyang 46
Hebei 44
Salerno 43
Helsinki 42
Jiaxing 37
Changsha 35
Washington 34
Pune 31
Falls Church 26
Tianjin 26
Los Angeles 23
Hong Kong 22
Norwalk 22
New York 19
Dallas 18
Vienna 18
Brno 17
Venezia 17
Cambridge 16
Nuremberg 16
Redwood City 15
Seattle 14
Guangzhou 12
Ottawa 12
San Diego 12
São Paulo 12
Paris 11
Amman 10
Milan 10
Tappahannock 10
Shanghai 9
Dearborn 8
London 8
Rome 8
Brasília 7
Chicago 7
Indiana 7
Napoli 7
San Francisco 7
Sarno 7
Castellammare di Stabia 6
Jinan 6
Jyväskylä 6
Warsaw 6
Belo Horizonte 5
Bologna 5
Hangzhou 5
Mercato San Severino 5
Mountain View 5
Porto Alegre 5
Rutigliano 5
Shijiazhuang 5
The Dalles 5
Zhengzhou 5
Amsterdam 4
Baghdad 4
Lappeenranta 4
Ningbo 4
Redmond 4
Rio de Janeiro 4
Tokyo 4
Yellow Springs 4
Yiwu 4
Angri 3
Ashdod 3
Auckland 3
Baoding 3
Bishkek 3
Chongqing 3
Contagem 3
Cuiabá 3
Des Moines 3
Fisciano 3
Florence 3
Fort Worth 3
Goiânia 3
Totale 11.862
Salva come PNG Salva come JPEG
Nome #
Differential sensitivity to non-MHC-restricted rIL-2 activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or PKA subunits. 336
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. 251
Abstract 3132: Single nucleotide polymorphisms (SNPs) in PD-L1 as predictive biomarkers for checkpoint inhibitor based-immunotherapy in caucasian patients with advanced NSCLC 214
Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. 150
Phase I clinical study with 8-Chloro-cAMP and evaluation of immunological effects in cancer patients. 150
Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture. 132
Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. 130
Anti-sense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. 128
Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. 127
Recombinant IFN-alfa 2b treatment activates poly (ADPR) polymerase-1 (PARP-1) in KB cancer cells. 125
NM23 gene expression correlates with cell growth rate and S-phase. 124
Epidermal growth factor receptor (EGFr) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype 121
ADDITION OF ERLOTINIB TO FLUROPYRIMIDINE-OXALIPLATIN-BASED CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB: TWO SEQUENTIAL PHASE I TRIALS. 121
Regulation of the expression of Fc-epsilon-R in the human monocyte like cell line U937 by TPA and IgE. 121
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 (‘Iressa’) 120
A phase I-II trial of gefitinib (IRESSA) and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN) 120
Additive effects of c-erbB-2, c-Ha-ras, and transforming growth factor-a genes on in vitro transformation of human mammary epithelial cells. 119
Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. 117
5-Aza-2'-Deoxycitidine induces growth-inhibition and up-regulation of epidermal-growth factor receptor on human epithelial cancer-cells 116
Down-regulation of RI alpha subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. 115
Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients 115
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FLFOX-4) as first-line treatment of advanced gastric cancer patients. 113
Synergistic anti-tumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells. 112
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting Protein Kinase A in combination with docetaxel and anti-EGFR-Receptor antibody on human breast cancer cell growth. 112
Reduction of RIAlpha subunit of cAMP-dependent Protein-Kinase expression induces growth-inhibition of human mammary epithelial-cells transformed by TGF-Alha, C-HA-RAS, and C-ErbB2 genes. 112
TSH-regulated growth and cell cycle distribution of thyroid cells involve type I isozyme of cAMP-dependent protein kinase 111
Loss of thyrotropin regulation and trasforming growth factor beta-induced growth arrest in erbB-2 overexpressing rat thyroid cells. 111
Adjuvant treatment of diabetic foot 110
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase C beta inhibitor, in non-small cell lung cancer cells. 109
Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study. 109
8-Cl-cAMP in differentiation therapy: The reversal and suppression of malignancy targeting the intracellular transducing proteins of cAMP. 109
Oral antisense targeting protein kinase A type I causes antitumor and apoptotic effect in human cancer cells in vitro and in vivo and has cooperative activity in combination with antisense bcl-2. 109
DNA index of ovarian carcinomas from 56 different patients: in vivo, in vitro studies. 107
TGFb inhibits rat thyroid cell proliferation without alterations in the expression of THS-induced cell cycle-related genes. Vol :pp , 106
Adjuvant Treatment for Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy: When, and for Whom? 106
DNA-flow cytometry (ploidy and S-phase fraction) as prognostic factor in a retrospectine series of 515 primary breast cancer. 105
Antitumor activity of BRAF inhibitor and IFN×alpha; Combination in BRAF-mutant melanoma 105
Cell growth-inhibition and cell cycle perturbations induced by a new synthetic iminoquinone, 5H-pyridophenoxazin-5-one, in human breast carcinoma cell lines. 104
Type-I isoform of PKA is involved in the control of cell proliferation and oncogene transformation of human mammary epithelial cells.Therapeutic implications 103
Inhibition of NF-kB activity potentiates ionizing radiation and cisplatin induced cell killing of anaplastic thyroid carcinoma cells AACR Meeting Abstracts, Apr 2006; 2006: 1038. 102
Growth inhibition of tumor cells by epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is associated with upregulation of p27 and p21 cyclin-dependent kinase inhibitors. 102
Critical role of both p27kip1 and p21cip1/waf1 in the antiproliferative effect of ZD1839 (‘Iressa’), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. 101
The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. 101
Predictive factors of response to neoadjuvant chemoradiotherapy in rectal cancer patirnts. 101
PRECLINICAL AND PHASE I STUDY OF OXALIPLATIN AND TOPOTECAN IN COMBINATION IN HUMAN CANCER. 101
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. 100
POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 1 EXPRESSION IN MALIGNANT MELANOMAS FROM PHOTOEXPOSED AREAS OF THE HEAD AND NECK REGION. 98
Blast cells DNA content in childhood leukemias. 97
Growth arrest, apoptosis and potentiation of 5-fluorouracil and Raltitrexed cytotoxic effect induced by histone deacetylase inhibitor SAHA in colorectal cancer cells. 97
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 96
IgE receptors. 96
The farnesyltransferase inhibitor R115777 (Zanestra) synergizes with ionizing radiation in inducing cell cycle perturbation and growth inhibition of human epidermoid head and neck cancer cells. 95
Suppression of malignancy targeting the intracellular signal transducing proteins of cAMP: the use of site selective cAMP analogs, antisense strategy, and gene-transfer. 95
Cell ploidy in 19 Wilms tumors by flow-cytometry of cell suspensions prepared from paraffina embedded sections. 95
EGF-R tyrosyne kinase as new target in melanoma treatment; Synergistic effect of IFN alpha in combination with ZD1839 )Iressa) , an EGFR tyrosine kinase inhibitor. 94
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. 93
Overexpression of wild-type p53 ovverrides the mitogenic effect of the RIa subunit of protein kinase A in human breast cells. 93
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. 93
8-Chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in human colon cancer cells 92
Multidisciplinary Approach to Patient with Malignant Melanoma 92
Epidermal growth factor (EGFR) and Transferrin (TRFR) receptor upregulation is induced by arabinoside cytosine (ARA-C) on human tumor cells. 91
EPIGENETIC FACTORS IN HEREDITARY BREAST CANCER 91
Synerglstic antltumor effect by novel modified oligonucleotides targeting PKAI combined with cytotoxic drugs or monoclonal antibodies. 91
Bevacizumab maintenance in metastatic colorectal cancer: How long?. 91
Tumori Eredo-Familiari 90
Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. 88
P53 expression in non-small-cell lung-cancer. Clinical and biological correlations. 88
Altre Neoplasie 88
Cooperative effect of 8-Cl-cAMP and rhGM-CSF on the differentiation of HL-60 human leukemia-cells. 88
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 87
Key role of the cyclin-dependent kinase inhibitor p27kip1 for embryonal carcinoma cell survival and differentiation. 87
Antisense-protein kinase A: a single-gene-based therapeutic approach. 87
Phase I-II study of sequential combination of XELOX and bevacizumab plus erlotinib (XELOX-TARAV) in first line colorectal patients:Run in phase I part 87
REPLY TO BRCA2 SPLICE SITE MUTATIONS IN ITALIAN BREAST/OVARIAN CANCER FAMILY. 87
p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. 86
Markers of cell-proliferation (p21, PCNA, S-Phase) as prognostic factors in papillary thyroid carcinoma. 86
Antitumor Agents. 5. Synthesis, structure−activity relationships, and biological evaluation of dimethyl-5H-pyridophenoxazin-5-ones, tetrahydro-5H-benzopyridophenoxazin-5-ones, and 5H-benzopyridophenoxazin-5-ones with potent antiproliferative activity. 86
Antisense DNA-targeting protein kinase A-RIA subunit: a novel approach to cancer treatment. 85
Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer. 85
Flow-cytometric detection of the RI-alpha subunit of Type-I cAMP-dependent protein-kinase in human-cells 85
Synergistic antitumor activity of the combination of the multi-targetes tyrosine kinase inhibitor sorafenib and of EGFR inhibitors in human colon and lung cancer cell lines. 85
Counteracting resistance to treatments in solid tumors. 85
Theophylline-induced apoptosis is paralleled by protein kinase A-dependent tissue transglutaminase activation in cancer cells. 85
Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma 85
EGF activates an inducible survival response via the RAS -> Erk-1/2 pathway to counteract interferon-alfa-mediated apoptosis in epidermoid cancer cells. 84
Overexpression of the RIα subunit of Protein Kinase A confers hypersensitivity to topoisomerase II inhibitors and 8-Chloro-cyclic Adenosine 3′,5′-Monophosphate in chinese hamster ovary cells. 84
Diagnostic utility of BRAFV600E mutation testing in thyroid nodules in elderly patients 83
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-A in head and neck cancer cells in vitro and in vivo 83
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 83
Phorbol-12-myristate-13-acetate (PMA) induces resistance of human melanoma cells to NK and LAK-mediated cytotoxicity. 83
Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. 83
TESI DI DOTTORATO: Hereditary and familial breast and ovarian cancer: spectrum of related tumors. CANDIDATO: M.Pensabene. RELATORE: S.Pepe 83
Unhydrolyzable analogs of Adenosine 3'/5'-monophosphate demonstrating growth-inhibition and differentiation in human cancer-cells. 83
Introducing an autophosphorylation site mutation in the RII-beta regulatory subunit of cAMP-dependent Protein-Kinase abolishes the RII-beta -mediated regulatory function. 83
cAMP-dependent protein kinase: role in normal and malignant growth. 82
Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway death is antagonized by epidermal growth factor. 82
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors: a phase I study. 82
Quality control for the evaluation of the S-phase fraction by flow cytometry: a multicentric study. 81
The cancer spectrum related to hereditary and familial breast and ovarian cancers 81
Retroviral vector-mediated overexpression of the RIIbeta subunit of the cAMP-dependent protein kinase induces differentiation in human leukemia cells and reverts the transformed phenotype of mouse fibroblasts. 81
Totale 10.454
Salva come PNG Salva come JPEG
Categoria #
all - tutte 46.986
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 46.986
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020217 0 0 0 0 0 0 0 0 0 0 195 22
2020/20211.355 13 151 155 14 164 30 171 11 153 2 168 323
2021/20221.181 4 0 3 35 30 39 15 54 189 161 141 510
2022/20231.923 190 91 53 246 271 420 2 169 357 10 74 40
2023/20241.135 80 136 66 27 67 142 276 61 28 39 47 166
2024/20251.824 78 33 52 94 147 364 392 242 317 102 3 0
Totale 15.682